Takeda Pharmaceutical Company Limited (VIE:TKD)
Austria · Delayed Price · Currency is EUR | Market Cap | 43.59B +5.9% |
| Revenue (ttm) | 24.58B -1.7% |
| Net Income | -831.22M |
| EPS | -0.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.11 (4.04%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | n/a |
| Open | 27.71 |
| Previous Close | 27.40 |
| Day's Range | 27.69 - 27.71 |
| 52-Week Range | 22.83 - 32.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About VIE:TKD
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
News
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Repres...
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin re...
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage hea...
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-...
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Appl...
Takeda Pharmaceutical Company Transcript: Jefferies Global Healthcare Conference 2026
Leadership transition is underway with Julie Kim as CEO, supported by a refreshed executive team and board. Three major product launches are expected to drive growth, while a transformation plan aims for significant cost savings and improved margins. ENTYVIO and plasma-derived therapies remain key revenue drivers amid evolving market dynamics.
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version o...
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda Pharmaceutical Company Earnings Call Transcript: Q4 2026
FY 2025 saw resilient financials despite VYVANSE erosion, with core revenue at JPY 4.5T and strong pipeline progress. Three late-stage assets are set for launch, supporting a new growth phase, while cost discipline and transformation programs underpin future margin expansion and capital flexibility.
Takeda Pharmaceutical Company Slides: Q4 2026
Takeda Pharmaceutical Company has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Takeda Pharmaceutical Company Quarterly report: Q4 2026
Takeda Pharmaceutical Company has published its Q4 2026 quarterly earnings report on May 13, 2026.
Takeda Pharmaceutical Company Annual report: Q4 2026
Takeda Pharmaceutical Company has published its Q4 2026 annual report on May 13, 2026.
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with i...
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Takeda Pharmaceutical said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage cli...
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Takeda Pharmaceutical Company Transcript: Study Update
Phase III studies show zasocitinib delivers rapid, durable skin clearance and significant quality-of-life improvements for moderate-to-severe plaque psoriasis, outperforming apremilast and placebo. The once-daily oral therapy demonstrated a strong safety profile and is positioned to expand the oral psoriasis market.
Takeda Pharmaceutical Company Slides: Study Update
Takeda Pharmaceutical Company has posted slides in relation to its latest quarterly earnings report, which was published on March 28, 2026.
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Takeda Pharmaceutical Company Transcript: TD Cowen 46th Annual Health Care Conference
Three NMEs are set for launch following strong phase III results, with a new CEO transition and a focus on digital transformation. Oveporexton, zasocitinib, and rusfertide each target distinct markets with robust efficacy and safety profiles, while pipeline expansion and new indications are planned.
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Dr...
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can off...
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1.
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecul...
Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today ann...